New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
09:17 EDTFLXNFlexion has a conference call hosted by BMO Capital
Specialty Pharmaceuticals Analyst Maris hosts a conference call with CEO Clayman and CFO Driscoll on March 12 at 10 am.
News For FLXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
10:01 EDTFLXNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: EVERTEC (EVTC) initiated with a Buy at Topeka... Express (EXPR) initiated with a Buy at Brean Capital... Flexion (FLXN) initiated with a Buy at MLV & Co.... HomeAway (AWAY) initiated with a Long-Term Buy at Hilliard Lyons... IAC (IACI) initiated with an Outperform at JMP Securities... INC Research (INCR) initiated with an Outperform at Raymond James... L Brands (LB) initiated with a Hold at Brean Capital... Masonite (DOOR) initiated with an Equal Weight at Stephens... MaxPoint Interactive (MXPT) initiated with a Buy at Deutsche Bank... NGL Energy Partners (NGL) initiated with an Equal Weight at Barclays... Neovasc (NVCN) initiated with an Outperform at Northland... New York & Co. (NWY) initiated with a Buy at Brean Capital... Pacific Biosciences (PACB) initiated with an Equal Weight at Stephens... Rice Midstream (RMP) initiated with an Outperform at Wells Fargo... Sensient (SXT) initiated with a Buy at BB&T... Skullcandy (SKUL) initiated with a Buy at Wunderlich... Ultragenyx (RARE) initiated with a Buy at MLV & Co.... Virgin America (VA) initiated with a Hold at Stifel... ZAGG (ZAGG) initiated with a Buy at Wunderlich.
March 30, 2015
17:44 EDTFLXNFlexion initiated with a Buy at MLV & Co.
Subscribe for More Information
March 23, 2015
16:11 EDTFLXNFlexion provides outlook on 2015
Michael Clayman, M.D., President and CEO of Flexion, stated, "For Flexion Therapeutics, 2014 was a transformational year. We completed two public stock offerings that place the company in a strong position to execute on its business plan. To that end, the Flexion team has advanced FX006 into two pivotal clinical trials that we expect will form the basis for a regulatory submission for a product that has the potential to make a meaningful and durable difference for the many patients suffering from OA knee pain. In addition, we strengthened our board of directors and management team." Dr. Clayman continued, "We expect 2015 to be another important year for the company as the readout from our first pivotal trial will happen later this year along with completion of enrollment in our Phase 3 trial. With positive data from both trials we look forward to the prospect of filing a New Drug Application thereafter." In 2015, the company expects to announce the results of pivotal Phase 2b trial in the fourth quarter and complete final, pivotal Phase 3 clinical trial enrollment for FX006.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use